MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

Strona główna・Stock List・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Closed

SectorHealthcare

28.79 -1

Buy Sell

Overview

Share price change

24h

Current

Min

28.7

Max

29.43

Key metrics
By Trading Economics
Income	-28M 22M
Sales	4.3M 244M
P/E Sector Avg	10.225 66.418
Profit margin	9.224
Employees	293
EBITDA	-22M 52M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+41.46% upside

Dividends
By Dow Jones
Next Earnings	5 maj 2026

Market Stats
By TradingEconomics
Market Cap	55M 1.6B
Previous open	29.79
Previous close	28.79

News Sentiment

By Acuity

34%

66%

123 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

29.8 / N/A Support & Resistance

Harmony Biosciences Holdings Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

10 kwi 2026, 17:04 UTC

Major Market Movers

FDA Rejects Replimune's Melanoma Drug for a Second Time

11 kwi 2026, 00:00 UTC

Earnings

Acquisitions, Mergers, Takeovers

Big Yachts, Big Bucks -- Barrons.com

10 kwi 2026, 21:55 UTC

Acquisitions, Mergers, Takeovers

Paramount Warrants Are an Underappreciated Aspect of Warner Bros. Deal -- Barrons.com

10 kwi 2026, 21:01 UTC

Earnings

Cango Inc.: Files Annual Report on Form 20-F With SEC

10 kwi 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

10 kwi 2026, 20:50 UTC

Market Talk

Major News Events

Basic Materials Roundup: Market Talk

10 kwi 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

10 kwi 2026, 20:31 UTC

Market Talk

Convenience Store Traffic Slows as Gas Prices Rise -- Market Talk

10 kwi 2026, 20:10 UTC

Acquisitions, Mergers, Takeovers

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10 kwi 2026, 19:15 UTC

Market Talk

Global Energy Roundup: Market Talk

10 kwi 2026, 19:15 UTC

Market Talk

Oil Futures Settle Lower With Focus on U.S.-Iran Talks -- Market Talk

10 kwi 2026, 19:08 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

10 kwi 2026, 19:08 UTC

Market Talk

U.S. Natural Gas Futures End Week Lower -- Market Talk

10 kwi 2026, 18:38 UTC

Market Talk

Canada's Job Market Showing Soft Demand, Structural Decline in Supply -- Market Talk

10 kwi 2026, 18:25 UTC

Market Talk

Major News Events

Precious Metals Finish With Weekly Gains -- Market Talk

10 kwi 2026, 18:05 UTC

Market Talk

Rising Commodity Prices Seen Carrying More Weight Than Jobs Data for Bank of Canada Watchers -- Market Talk

10 kwi 2026, 17:31 UTC

Market Talk

Major News Events

U.S. Oil Rig Count Unchanged This Week At 411 -- Market Talk

10 kwi 2026, 17:26 UTC

Earnings

Big Banks' Profits Set to Rise Even as 'Wall of Worry' Looms -- Barrons.com

10 kwi 2026, 17:10 UTC

Market Talk

White House Defense of Stablecoin Yields Is Welcome Move, Grayscale Says -- Market Talk

10 kwi 2026, 17:00 UTC

Major News Events

Construction Business Taking a Hit From Iran Conflict -- WSJ

10 kwi 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

10 kwi 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

10 kwi 2026, 16:12 UTC

Earnings

Partners Group CEO: Group Well Positioned to Navigate Current Complex Environment

10 kwi 2026, 16:11 UTC

Earnings

Partners Group: Traditional Programs Contributed $3.3B

10 kwi 2026, 16:10 UTC

Earnings

Partners Group: $5B of New Commitments Came From Bespoke Solutions

10 kwi 2026, 16:10 UTC

Earnings

Partners Group: That Is Across All Private Markets Asset Classes and Client Strategies

10 kwi 2026, 16:10 UTC

Earnings

Partners Group 1Q New Client Demand $8.3B

10 kwi 2026, 16:09 UTC

Earnings

Partners Group Continued to See Positive Fundraising Momentum in 1Q

10 kwi 2026, 15:54 UTC

Acquisitions, Mergers, Takeovers

Plenitude Completes Acquisition of Acea Energia

10 kwi 2026, 15:38 UTC

Market Talk

Global Energy Roundup: Market Talk

Peer Comparison

Price change

Harmony Biosciences Holdings Inc Forecast

Price Target

By TipRanks

41.46% upside

12 Months Forecast

Average 41.25 USD 41.46%

High 62 USD

Low 25 USD

Based on 8 Wall Street analysts offering 12 month price targets forHarmony Biosciences Holdings Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Harmony Biosciences Holdings Inc - Dist in the past 3 months.

Technical Score

By Trading Central

29.8 / N/ASupport & Resistance

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

123 / 348 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.